ArticleCureus2026
Life-Threatening Hypokalemia Revealing CACNA1S-Related Hypokalemic Periodic Paralysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial hypokalemic periodic paralysis (HypoPP) is a rare autosomal dominant skeletal muscle channelopathy most commonly caused by pathogenic variants in the CACNA1S gene. It is characterized by recurrent episodes of severe hypokalemia and transient flaccid paralysis resulting from intracellular potassium redistribution rather than true potassium depletion. Despite advances in molecular genetics, familial HypoPP remains underrecognized, particularly in regions where acquired causes such as thyrotoxic periodic paralysis predominate. We report a young adult male presenting with recurrent episodes of severe hypokalemia complicated by cardiac conduction abnormalities and requiring intensive care management. A systematic diagnostic evaluation, including next-generation sequencing, was undertaken to exclude secondary and renal causes of hypokalemia. Genetic analysis identified a heterozygous pathogenic CACNA1S variant (c.1583G>A; p.Arg528His), confirming hypokalemic periodic paralysis type 1 (HypoPP1). This case highlights the importance of a structured diagnostic approach to recurrent hypokalemia and emphasizes the role of molecular testing in distinguishing familial channelopathies from more common acquired etiologies. We further discuss genotype-phenotype correlations, variable penetrance, implications for family screening, and emerging genotype-guided therapeutic strategies in hypokalemic periodic paralysis. The report underscores the growing importance of molecular diagnostics in the evaluation and management of rare neuromuscular channelopathies within the framework of contemporary precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.